Inclusive of all taxes
Liposomal Amphotericin B Injection is a highly effective antifungal pharmaceutical specifically formulated for the treatment of severe systemic fungal infections and leishmaniasis. Utilizing liposomal technology, the drug encapsulates Amphotericin B in lipid vesicles, enhancing its delivery and reducing toxicity compared to conventional formulations. This injectable preparation ensures targeted treatment by providing better tissue penetration, reduced nephrotoxicity, and improved patient tolerance. It is particularly beneficial in immunocompromised patients, including those with AIDS or undergoing chemotherapy, where invasive fungal infections pose a high risk. In addition, Liposomal Amphotericin B Injection is indicated for visceral leishmaniasis, offering a potent therapeutic option with a better safety profile. Manufactured under stringent pharmaceutical standards, this injection serves as a critical intervention for healthcare professionals managing complicated fungal infections and parasitic diseases in clinical settings.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Amphotericin B encapsulated in liposomes |
| Formulation Type | Intravenous Injection |
| Indications | Severe fungal infections, Leishmaniasis |
| Advantages | Reduced nephrotoxicity, Enhanced efficacy, Improved tissue penetration |
| Dosage Form | Sterile injectable suspension |
| Target Patient Group | Immunocompromised patients, Patients with systemic infections |
| Packaging | Single-use vials in controlled volumes |
| Storage Conditions | Store at 2°C to 8°C, protect from light |
| Manufacturing Standards | Produced under GMP compliance |
| Administration Route | Intravenous infusion |
| Attributes | Description |
|---|---|
| Concentration | Typically 50 mg per vial |
| Shelf Life | 24 months from manufacturing date |
| Liposomal Carrier | Phospholipid bilayer liposomes |
| Reconstitution | Dilute as per protocol before administration |
| Packaging Type | Glass vial with rubber stopper and aluminum seal |
| Regulatory Compliance | Manufactured as per international pharmacopoeia standards |
| Usage Guidance | Use strictly under medical supervision |
| Side Effects Profile | Lower nephrotoxicity; monitor renal function during therapy |
| Pharmacokinetics | Enhanced circulation half-life due to liposomal encapsulation |
| Compatibility | Compatible with standard IV fluids |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The liposomal encapsulation reduces exposure of Amphotericin B to the kidneys, thereby significantly lowering nephrotoxicity, while enhancing targeted delivery to infected tissues.
Yes, this formulation is especially recommended for immunocompromised patients as it offers effective antifungal action with reduced side effects.
The injection should be stored refrigerated between 2°C and 8°C and protected from light to ensure stability and efficacy.
Yes, it is indicated for visceral leishmaniasis treatment and provides a safer alternative to conventional therapy.
The injection commonly comes in 50 mg vials, and dosing should be strictly followed as per medical prescription.
Country Of Origin: India
Liposomal Amphotericin B Injection is an antifungal medication. It is used in the treatment of severe fungal infections and leishmaniasis.
Inclusive of all taxes
You Save: 0
